Skip to main content
. 2018 Feb 21;2(1):e31. doi: 10.1097/HS9.0000000000000031

Figure 6.

Figure 6

Childhood AML outcome. (A) Childhood AML outcome according to the molecular classifier. Favorable molecular risk: RUNX1–RUNX1T1 or CBFB–MYH11 or NPM1 mutation or CEBPAdm; poor molecular risk: NUP98 fusion or RUNX1 or WT1 or PHF6 mutation; intermediate molecular risk (all others). (B) Childhood AML outcome according to the 2017 European LeukemiaNet (ELN) classification.21